aproxen as an adjuvant therapy for the treatment of obsessive-compulsive disorder (OCD)
Phase 2
- Conditions
- Obsessive-compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT20090117001556N139
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Age between 18 to 60 years old
Diagnosis of OCD based on DSM-5
Score of >21 in Yale–Brown obsessive-compulsive scale (Y-BOCS)
Exclusion Criteria
Receiving any treatment up to 6 weeks before the start of the trial
Diagnosis of another psychiatric disorder
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of OCD symptoms. Timepoint: Baseline and weeks 5 and 10. Method of measurement: By Yale–Brown obsessive-compulsive scale (Y-BOCS).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie aproxen's adjuvant effect in OCD (IRCT20090117001556N139) via COX inhibition?
How does aproxen as an adjuvant compare to SSRIs in reducing OCD symptoms in phase II trials (IRCT20090117001556N139)?
Which biomarkers predict response to aproxen as an adjuvant in OCD (IRCT20090117001556N139) patients?
What are the adverse events associated with aproxen as an adjuvant in OCD (IRCT20090117001556N139) and their management strategies?
What other COX-2 inhibitors or anti-inflammatory agents are being studied as adjuvants for OCD alongside aproxen (IRCT20090117001556N139)?